HXHan Xu

Han Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Han Xu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HRCHY-CytoCommunity identifies hierarchical tissue organization in cell-type spatial maps

    by Runzhi Xie, Zekun Wang, Jianrui Liu, Han Xu, Yafei Xu, Jiadong Lin, Yuxuan Hu, Lin Gao

    Tissues are organized through the assembly of diverse cell types into multicellular structures that exhibit hierarchical spatial organization. We present HRCHY-CytoCommunity, a graph neural network framework for identifying multi-level tissue structures directly from cell-type annotated spatial maps. It integrates differentiable graph pooling, adaptive edge pruning, and consistency and balance regularization in an end-to-end model, simultaneously inferring robust structures across multiple scales while preserving complete cellular coverage and fully nested relationships. The framework also supports cross-sample hierarchy alignment via cell-type enrichment-based clustering. Benchmarking on diverse spatial omics datasets, HRCHY-CytoCommunity outperforms existing hierarchical and non-hierarchical methods in identifying both coarse-grained tissue compartments and fine-grained cellular neighborhoods. Applied to a breast cancer cohort with clinical outcomes, the framework enables hierarchical prognostic stratification of patients and reveals survival-associated spatial patterns. HRCHY-CytoCommunity represents a general and scalable tool for deciphering tissue organization from single cells to multicellular modules, and ultimately to intact tissues and organs.


  • Open Access

    Evaluation and comparison of multi-omics data integration methods for cancer subtyping

    by Ran Duan, Lin Gao, Yong Gao, Yuxuan Hu, Han Xu, Mingfeng Huang, Kuo Song, Hongda Wang, Yongqiang Dong, Chaoqun Jiang, et al.

    Computational integrative analysis has become a significant approach in the data-driven exploration of biological problems. Many integration methods for cancer subtyping have been proposed, but evaluating these methods has become a complicated problem due to the lack of gold standards. Moreover, questions of practical importance remain to be addressed regarding the impact of selecting appropriate data types and combinations on the performance of integrative studies. Here, we constructed three classes of benchmarking datasets of nine cancers in TCGA by considering all the eleven combinations of four multi-omics data types. Using these datasets, we conducted a comprehensive evaluation of ten representative integration methods for cancer subtyping in terms of accuracy measured by combining both clustering accuracy and clinical significance, robustness, and computational efficiency. We subsequently investigated the influence of different omics data on cancer subtyping and the effectiveness of their combinations. Refuting the widely held intuition that incorporating more types of omics data always produces better results, our analyses showed that there are situations where integrating more omics data negatively impacts the performance of integration methods. Our analyses also suggested several effective combinations for most cancers under our studies, which may be of particular interest to researchers in omics data analysis.


  • Open Access

    CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping

    by Ran Duan, Lin Gao, Han Xu, Kuo Song, Yuxuan Hu, Hongda Wang, Yongqiang Dong, Chenxing Zhang, Songwei Jia

    Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, there are no consistent criteria to evaluate the integration methods due to the lack of gold standards (e.g. the number of subtypes in a specific cancer). Since comprehensive evaluation and comparison between different methods serves as a useful tool or guideline for users to select an optimal method for their own purpose, we develop a scalable platform, CEPICS, for comprehensively evaluating and comparing multi-omics data integration methods in cancer subtyping. Given a user-specified maximum number of subtypes, k-max, CEPICS provides: (1) cancer subtyping results using up to five built-in state-of-the-art integration methods under the number of subtypes from two to k-max, (2) a report including the evaluation of each user-selected method and comparisons across them using clustering performance metrics and clinical survival analysis, and (3) an overall analysis of subtyping results by different methods representing a robust cancer subtype prediction for samples. Furthermore, users can upload subtyping results of their own methods to compare with the built-in methods. CEPICS is implemented as an R package and is freely available at https://github.com/GaoLabXDU/CEPICS.


  • Proteomics‐based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins

    by Jianen Gao, Yuan Gao, Yanfang Ju, Jinju Yang, Qiong Wu, Jinchao Zhang, Xuemei Du, Zhaoqing Wang, Yingbo Song, Hui Li, et al.

    Monoclonal antibodies (mAbs) have the potential to be a very powerful tool in proteomics research to determine protein expression, quantification, localization and modification, as well as protein‐protein interactions, especially when combined with microarray technology. Thus, a large amount of well‐characterized and highly qualified antibodies are needed in proteomics. Purified antigen, which is not always available, has proven to be one of the rate‐limiting steps in mAb large‐scale generation. Here we describe our strategies to establish a murine hybridoma cell bank for human liver mitochondria using unknown native proteins as the immunogens. The antibody‐recognized mitochondrial proteins were identified by MS following immunoprecipitation (IP), and by screening of human liver cDNA expression library. We found that the established antibodies reacted specifically with a number of important enzymes in mitochondria. The subcellular localization of these antigens in mitochondria was further confirmed by immunohistocytochemistry. A panel of antibodies was also tested for their ability to capture and deplete the targeting proteins and complexes from the total mitochondrial proteins. We believe these well‐characterized antibodies would be useful in various applications for Human Liver Proteome Project (HLPP) when the scale of this hybridoma cell bank is enlarged significantly in the near future.